Cargando…

HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks

Around 20% of breast cancers are associated with amplification or overexpression of human epidermal growth factor receptor 2 (HER2). In this setting, anti-HER2-targeted agents are the cornerstone of cancer therapeutic strategies. This includes monoclonal antibodies, tyrosine kinase inhibitors (TKIs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mandó, Pablo, Waisberg, Federico, Pasquinelli, Rosario, Rivero, Sergio, Ostinelli, Alexis, Perazzo, Florencia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948634/ https://www.ncbi.nlm.nih.gov/pubmed/36844609 http://dx.doi.org/10.2147/OTT.S335934

Ejemplares similares

Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era
por: Mandó, Pablo, et al.
Publicado: (2021)

Burnout syndrome in medical oncologists during the COVID-19 pandemic: Argentinian national survey
por: Guercovich, Andres, et al.
Publicado: (2021)

Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer – Proceedings from breast cancer expert group meeting
por: Dawood, Shaheenah, et al.
Publicado: (2021)

Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database
por: Fabiano, Verónica, et al.
Publicado: (2020)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
por: LeVee, Alexis, et al.
Publicado: (2023)

Emerging Targeted Therapies for HER2-Positive Breast Cancer
por: Mercogliano, María Florencia, et al.
Publicado: (2023)

The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
por: Lewis, Gary. D., et al.
Publicado: (2021)

Targeting HER2-positive breast cancer: advances and future directions
por: Swain, Sandra M., et al.
Publicado: (2022)

Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
por: Schlam, Ilana, et al.
Publicado: (2022)

Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review
por: Wang, Jin, et al.
Publicado: (2023)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

HER2 status and breast cancer therapy: recent advances
por: Tripathy, Debu
Publicado: (2009)

Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
por: Miles, David W
Publicado: (2009)

Clinical outcomes of patients with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed therapies
por: Zhou, Jiebai, et al.
Publicado: (2020)

The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
por: Mendes, Diogo, et al.
Publicado: (2015)

Update on HER2-directed therapy
por: Slamon, D
Publicado: (2005)

New Advances in Targeted Therapy of HER2-Negative Breast Cancer
por: An, Junsha, et al.
Publicado: (2022)

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
por: Morrow, Phuong Khanh H, et al.
Publicado: (2009)

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
por: de Melo Gagliato, Debora, et al.
Publicado: (2016)

Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer
por: Torrisi, Rosalba, et al.
Publicado: (2022)

Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly
por: Sun, J, et al.
Publicado: (2017)

Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
por: Wynn, Carrie S., et al.
Publicado: (2022)

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

Effect of HER2 expression status on the prognosis of patients with HR(+)/HER2(‑) advanced breast cancer undergoing advanced first‑line endocrine therapy
por: Wang, Kan, et al.
Publicado: (2023)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
por: Ma, Jing, et al.
Publicado: (2022)

Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy
por: MacNeil, Ian A., et al.
Publicado: (2022)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
por: Mitri, Zahi, et al.
Publicado: (2012)

Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management
Publicado: (2019)

Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management
por: Mahtani, Reshma, et al.
Publicado: (2019)

Advances in neoadjuvant therapy for HER2-positive breast cancers: a narrative review
por: Wang, Qianmu, et al.
Publicado: (2022)

Advances in Targeting HER3 as an Anticancer Therapy
por: Jiang, Ning, et al.
Publicado: (2012)

Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series
por: Rusz, Orsolya, et al.
Publicado: (2018)

Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
por: Ferrario, Cristiano, et al.
Publicado: (2022)

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
por: Geyer, Charles E., et al.
Publicado: (2018)

The benefits of trastuzumab in the treatment of HER2+ breast cancer as a function of exposure time
por: da Luz, Felipe Andrés Cordero, et al.
Publicado: (2022)

Adjuvant therapy of HER2(+ )breast cancer
por: Winer, EP
Publicado: (2009)

Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2
por: Narváez, Dana, et al.
Publicado: (2022)

HER2/neu-directed therapy for biliary tract cancer
por: Javle, Milind, et al.
Publicado: (2015)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_qiesgorkb1bj4ge4sd74ci81b8